103 related articles for article (PubMed ID: 2793381)
1. Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer.
Osborne CK; Craig JB; Klein K; Crawford ED; Turner J
Invest New Drugs; 1989 Jul; 7(2-3):243-5. PubMed ID: 2793381
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of ImuVert (natural membrane vesicles associated with ribosomes) in patients with advanced cancer.
Mittelman A; Urban R; Wong G; Ahmed T; Arlin Z
Cancer Immunol Immunother; 1992; 35(5):331-4. PubMed ID: 1394337
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma.
Jaeckle KA; Mittelman A; Hill FH
J Clin Oncol; 1990 Aug; 8(8):1408-18. PubMed ID: 2199624
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma.
Black KL; Ciacci JD; Ammirati M; Selch MT; Becker DP
J Clin Oncol; 1993 Sep; 11(9):1746-50. PubMed ID: 8394880
[TBL] [Abstract][Full Text] [Related]
5. An EORTC phase II study of vindesine in advanced prostate cancer.
Jones WG; Fosså SD; Denis L; Coninx P; Glashan RW; Akdas A; De Pauw M
Eur J Cancer Clin Oncol; 1983 May; 19(5):583-8. PubMed ID: 6683629
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.
Dreicer R; Kemp JD; Stegink LD; Cardillo T; Davis CS; Forest PK; See WA
Cancer Invest; 1997; 15(4):311-7. PubMed ID: 9246151
[TBL] [Abstract][Full Text] [Related]
7. ImuVert therapy in the treatment of recurrent malignant astrocytomas: nursing implications.
Cress NB; Owens BM; Hill FH
J Neurosci Nurs; 1991 Feb; 23(1):29-33. PubMed ID: 1826714
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
[TBL] [Abstract][Full Text] [Related]
10. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
Chiappino I; Destefanis P; Addeo A; Galetto A; Cucchiarale G; Munoz F; Zitella A; Ferrando U; Fontana D; Ricardi U; Tizzani A; Bertetto O
Am J Clin Oncol; 2007 Jun; 30(3):234-8. PubMed ID: 17551298
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
12. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
13. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
Dreicer R; Forest PK; Williams RD
Urology; 1994 Sep; 44(3):377-80. PubMed ID: 7521094
[TBL] [Abstract][Full Text] [Related]
15. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
Ferrero JM; Foa C; Thezenas S; Ronchin P; Peyrade F; Valenza B; Lesbats G; Garnier G; Boublil JL; Tchiknavorian X; Chevallier D; Amiel J
Oncology; 2004; 66(4):281-7. PubMed ID: 15218295
[TBL] [Abstract][Full Text] [Related]
16. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
[TBL] [Abstract][Full Text] [Related]
17. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Meluch AA; Spigel DR; Barton J; Simons L; Meng C; Gould B; Greco FA
Clin Genitourin Cancer; 2007 Mar; 5(4):278-83. PubMed ID: 17553208
[TBL] [Abstract][Full Text] [Related]
18. Weekly chemotherapeutic regimen in metastatic prostate cancer.
Burk K
Prog Clin Biol Res; 1989; 303():261-75. PubMed ID: 2674989
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a biologic response modifier derived from Serratia marcescens: effects on feline macrophages and usefulness for the prevention and treatment of viremia in feline leukemia virus-infected cats.
Elmslie RE; Ogilvie GK; Dow SW; Gasper P; Hoover EA; Cooper MF; Pearson FC
Mol Biother; 1991 Dec; 3(4):231-8. PubMed ID: 1768375
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the immune response of Balb/c mice against Leishmania major by imuvert.
Taha SM; Tabbara KS
Int J Immunopharmacol; 1997 Aug; 19(8):443-9. PubMed ID: 9568550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
